Datapoint: FDA Approves Avastin Biosimilar

October 4

The FDA last week approved Celltrion Healthcare’s Avastin biosimilar across six of the oncology powerhouse’s indications, including metastatic colorectal cancer and recurrent or metastatic non-squamous non-small cell lung cancer. The angiogenesis inhibitor, known as Vegzelma, is the sixth biosimilar to receive FDA approval this year. For the treatment of colorectal cancer, Avastin currently holds covered or better status for 51% of all insured lives under the pharmacy benefit, and 86% of insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 10/3/22